The compound you described, **1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinecarboxamide**, is a complex organic molecule with a specific structure. It is important for research because it exhibits **potential biological activity**.
Here's a breakdown of its components and potential significance:
**Structure:**
* **Benzothiadiazole (BTD):** A heterocyclic ring system known for its ability to absorb light in the UV-Vis range. This characteristic makes it useful in applications like dyes, pigments, and potentially in photoactive materials.
* **Sulfonyl Group:** A sulfur-containing group that often contributes to drug-like properties, including binding to proteins.
* **Piperidinecarboxamide:** A cyclic amine derivative that can interact with biological targets like enzymes and receptors.
* **3,4-Dimethoxyphenyl:** A substituted aromatic ring containing two methoxy groups (CH3O-). This group can influence the compound's solubility and interaction with biological systems.
**Potential Significance in Research:**
* **Drug Development:** This compound could potentially act as a **lead compound** for developing new drugs with therapeutic applications. The presence of a benzothiadiazole ring and a sulfonyl group suggests potential for targeting enzymes or receptors involved in various biological processes.
* **Materials Science:** The benzothiadiazole moiety might contribute to the compound's ability to absorb and emit light, potentially making it useful in **optoelectronic materials**, such as solar cells or light-emitting diodes.
* **Biological Studies:** The compound's structure and functional groups could be of interest in studying the interaction of organic molecules with biological systems. This might provide insights into **protein-ligand interactions**, **enzyme kinetics**, or **drug delivery mechanisms**.
**Important Note:** The specific biological activity and potential applications of this compound would depend on its detailed chemical properties and experimental testing. Without further information, it is impossible to determine its exact significance.
**To get a more comprehensive understanding of the compound's importance, you would need to research:**
* **Its specific biological activity:** Has it been tested for any particular therapeutic effect?
* **Its synthesis and characterization:** How was it prepared and what are its physical and chemical properties?
* **Its interaction with biological systems:** Does it bind to any specific proteins or receptors?
* **Its potential applications:** Is it being explored for any particular therapeutic or materials science use?
Researchers studying this compound are likely interested in its potential as a drug candidate or as a component in new materials with unique properties.
ID Source | ID |
---|---|
PubMed CID | 3242258 |
CHEMBL ID | 1523996 |
CHEBI ID | 112721 |
Synonym |
---|
AKOS001805989 |
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-4-carboxamide |
MLS000091777 |
smr000026324 |
MLS000876883 |
CHEBI:112721 |
STK853905 |
HMS2333I14 |
CHEMBL1523996 |
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinecarboxamide |
Q27192836 |
1-(2,1,3-benzothiadiazole-4-sulfonyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-4-carboxamide |
Class | Description |
---|---|
dimethoxybenzene | Any methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 31.6228 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
TDP1 protein | Homo sapiens (human) | Potency | 10.3225 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 8.9125 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
DNA polymerase beta | Homo sapiens (human) | Potency | 0.4467 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 25.1189 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |